- Home
- WDH vs CCCC Comparison
WDH vs CCCC Comparison
Compare WDH & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDH | CCCC |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 404.7M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WDH | CCCC |
|---|---|---|
| Price | $0.98 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 210.8K | ★ 2.3M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.71 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $0.96 | $1.69 |
| 52 Week High | $2.18 | $5.17 |
Technical Indicators
Market Signals| Indicator | WDH | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 27.34 | 49.51 |
| Support Level | $0.96 | $3.40 |
| Resistance Level | $1.02 | $4.49 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 31.96 | 36.35 |
Price Performance
Historical ComparisonAbout WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Companies main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The companies reportable segments are Insurance, Crowdfunding and Others.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.